Skip to main content
Premium Trial:

Request an Annual Quote

Waters' Q2 Profit Recedes, Dragging Down Shares

NEW YORK (GenomeWeb News) – Waters today reported that second-quarter revenue increased 6 percent as net income fell 12 percent on increased expenses, causing shares to slide 8.8 percent, or $3.75, to $38.85 in mid-afternoon trading.
 
Total receipts for the three months ended July 1 increased to $302 million from $285 million year over year. Waters said it is seeing strong demand for its Acquity UPLC technology.
 
Profit in the quarter declined to $48 million, or $.46 per share, from $54 million, or $.47 per share, last year. The company reported about $3 million in restructuring costs while expenses increased 7 percent in the quarter.
 
R&D spending increased 25 percent to about $20 million from $16 million in the year-ago period.
 
As of July 1, Waters had $490 million in cash and cash equivalents.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.